pharma news today obesity drugs glp-1 Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began.⁠ ⁠ Having WHO GLP-1 Treatments: WHO Endorses

The rate at which the medical community is giving out these drugs tells me that were hitting a lot of people with a predisposition for eating disorders. Turner hopes that clinicians prescribing these drugs will take screening for eating disorders seriously and recognize that people can have eating disorders at every size

Nausea, vomiting and diarrhoea are some of the most common side effects

A prodrome suggesting a viral illness may lead to gastroparesis

Pratter died unexpectedly, potentially delaying further action with the process until a new judge can be assigned

The price variations reflect differences in provincial markup regulations, pharmacy dispensing fees, and wholesale purchasing agreements

Imagine if you were a big drug company with shareholders, profits to lose, etc., and you just spent ~$1 billion and ~10 years to bring a drug to market